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Abstract
In a clinical infection, multiplying and non-multiplying bacteria co-exist. Antibiotics kill multiplying bacteria, but they are
very inefficient at killing non-multipliers which leads to slow or partial death of the total target population of microbes in an
infected tissue. This prolongs the duration of therapy, increases the emergence of resistance and so contributes to the short
life span of antibiotics after they reach the market. Targeting non-multiplying bacteria from the onset of an antibiotic
development program is a new concept. This paper describes the proof of principle for this concept, which has resulted in
the development of the first antibiotic using this approach. The antibiotic, called HT61, is a small quinolone-derived
compound with a molecular mass of about 400 Daltons, and is active against non-multiplying bacteria, including methicillin
sensitive and resistant, as well as Panton-Valentine leukocidin-carrying Staphylococcus aureus. It also kills mupirocin resistant
MRSA. The mechanism of action of the drug is depolarisation of the cell membrane and destruction of the cell wall. The
speed of kill is within two hours. In comparison to the conventional antibiotics, HT61 kills non-multiplying cells more
effectively, 6 logs versus less than one log for major marketed antibiotics. HT61 kills methicillin sensitive and resistant S.
aureus in the murine skin bacterial colonization and infection models. No resistant phenotype was produced during 50 serial
cultures over a one year period. The antibiotic caused no adverse affects after application to the skin of minipigs. Targeting
non-multiplying bacteria using this method should be able to yield many new classes of antibiotic. These antibiotics may be
able to reduce the rate of emergence of resistance, shorten the duration of therapy, and reduce relapse rates.
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Introduction
The traditional route for identifying early hits in antibiotic
research is to target multiplying bacteria. All current antibiotics
have been generated this way. Activity of a potential antibiotic in
such assays is predictive of an antimicrobial effect in humans
(bearing in mind many compounds are not suitable due to
undesirable characteristics such as toxicity). The disadvantage of
this route is that the numbers of novel classes of non-toxic
compounds which kill multiplying bacteria may have been almost
exhausted [1] and those that remain, may require substantial effort
and expense to bring to market. Furthermore anti-multiplying
agents are almost always either inactive or only partially active
against non-multiplying or slowly multiplying or persister bacteria
[2,3,4,5,6] which leads to the need for multiple doses of antibiotics
in order to achieve cure of a bacterial infectious disease. This
prolongs the duration of therapy and increases the emergence of
resistance. Since bacterial resistance reduces the effectiveness of
antibiotics, new ones are required at regular intervals, as the old
ones lose their potency for most infections. However, the number
of new antibiotics which reach the market each year is falling
[1,3,5,7,8]. Whilst at least 15 classes of antibiotics were introduced
into the market between 1940 and 1962 [3], only three new classes
of antibiotics have been marketed since then [9,10,11]. Together
with their subsequent analogues, each class loses effectiveness, at
least for some species of bacteria such as Gram-negatives, within
50 years after entry into the market. So, if we continue to use
existing technologies for the next 50 years, it is unlikely that we will
produce enough new classes to prevent the antibiotic era fading
away. A fundamentally new route for antibiotic drug discovery is
required if the antibiotic era is to continue. Bacterial molecules
have been targeted, in order to create new drugs, but this has not
produced any new classes of antibiotics which have reached the
market [7]. Another potential way to develop new antibacterials is
to use bacteriophages. Although this method has been utilized for
decades, no marketed bacteriophages are available in Western
countries for licensed medicinal purposes.
We have proposed a new approach for the production of novel
classes of antibiotics [1,3]. This new route targets whole bacteria
which are in the non-multiplying stage from the beginning of the
discovery process. In a clinical infection, there is co-existence of
multiplying bacteria and non-multiplying bacteria [5,12]. Al-
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though non-multipliers do not cause overt disease, they act as a
pool from which multiplying bacteria emerge to cause recurrent
disease. Current antibiotics kill multiplying bacteria, but they are
very inefficient at killing non-multipliers [3,4,13,14] which leads to
slow or partial death of the total target population in an infected
tissue. This results in repeated administration of antibiotics and
leads to extended periods of antibiotic treatment. For example,
tuberculosis has a drug regimen lasting at least six months [15].
Bacterial endocarditis is treated for several weeks. Non-multipliers
probably also occur in many other common infections such as sore
throat and infected eczema [3,5,7,16]. In turn, these repeat-dose
drug treatments can result in the emergence of antibiotic resistance
associated with poor patient compliance [3,16]. These contribute
to the short life span of antibiotics when they reach the market. An
ideal antibiotic would swiftly kill all of the non-multiplying and
multiplying bacteria in an infected tissue, thereby shortening
antibiotic regimens. This process should slow the emergence of
genetic resistance, because mutation cannot occur if there are no
live target bacteria. Unfortunately, no marketed antibiotic lives up
to this ideal, and resistance is now widespread.
Here we describe a proof of principle study for a new approach
in which we have selected for a compound throughout the
discovery process that has activity against non-multiplying
bacteria. The lead compound, HT61 which is a topical antibiotic,
is more bactericidal for non-multiplying bacteria than marketed
antibiotics but is less potent against multiplying organisms. It does
not induce resistance over 50 passages of suboptimal treatment.
HT61 kills non-multiplying bacteria in an animal model, and is
not toxic when applied to the skin of minipigs. This compound is
now in clinical trials.
Results
Establishment of a long term non-multiplying stationary
phase model for drug selection
In order to establish stationary phase models, methicillin-
sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S.
aureus (MRSA) were grown in nutrient broth for 10 days. Viability
of the bacteria was determined by CFU counts at different time
points. As shown in Fig 1, the growth in both aerated cultures
reached peaks (1.56109 CFU/ml) at 24 hours of growth, the CFU
counts remained relatively constant until 6 days of incubation for
MSSA and 7 days for MRSA, then gradually decreased to a value
of about 36108 CFU/ml after 10 days of incubation.
Long-term stationary phase cultures of 5 to 6 days were chosen.
These late stationary phase cultures, as seen in Fig. 1, may
represent a mixed population with a dynamic balance of cell
division and cell death [17]. In order to induce the bacterial cells
into a non-replicating stage, we washed and incubated the cells
with PBS. No changes in CFU counts of the bacteria were
observed after 24 hours of incubation in the buffer (data not
shown) indicating that the bacteria were in a non-multiplying state.
The nutrient depleted 5–6 day stationary phase cell suspension
was used to screen or test drugs and was called non-multiplying
stationary phase bacteria.
Strategy of screening drugs against non-multiplying
bacteria
A previous study has demonstrated that fluoroquinolones such
as ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, and gati-
floxacin exhibit bactericidal activity against stationary phase and
persistent Mycobacterium tuberculosis [18]. We used a company,
Argenta Discovery UK, to search similar commercially available
structures to quinolones using a virtual screening technique. All 2-
D substructure and similarity searches were carried out in the
Argenta ‘‘Unity’’ database which comprised 952,601 commercial-
ly available, drug-like compounds collated from the collection of
over 40 suppliers worldwide. As a result of the computer aided
search, we chose 57 quinolone-like compounds which we obtained
commercially. We screened activities of these compounds against
non-multiplying MSSA using the model described above. We
found that only two of these compounds with similar structures
showed stationary phase bactericidal effects with 2–3 log kill of
non-multiplying bacteria. We used these active compounds as core
structures to synthesise analogues. Over 300 new derivative
compounds were synthesised by Argenta Discovery UK and were
screened for activity against non-multiplying S. aureus. We have
seleted many compounds showing bactericidal activity. One of
them, named HT61, is a quinolone-derived compound which
presented significant potency.
HT61 is more active against non-multiplying MSSA and
MRSA than selected marketed antibiotics
The activity of HT61 against non-multiplying MSSA was
compared with several marketed antibiotics. Non-multiplying
MSSA was incubated with different concentrations of HT61,
amoxicillin/clavulanic acid (Augmentin), azithromyicin, levoflox-
acin, linezolid, daptomycin and mupirocin for 24 hours, and the
activities of the drugs were measured by CFU counts. As shown in
Fig. 2A, HT61 kills over 7 log CFU/ml at a concentration of
12.5 mg/ml. The minimum stationary phase-cidal concentration
50 (MSC50) of HT61 is 2.5 mg/ml and the minimum stationary
phase-cidal concentration 99 (MSC99) was 4.5 mg/ml. In contrast,
amoxicillin/clavulanic acid (Augmentin), azithromyicin, levoflox-
acin, linezolid and mupirocin at 50 mg/ml failed to exhibit any
activities against the non-multiplying bacteria. Daptomycin
reduced the CFU counts from log 7 to 0 at 50 mg/ml. The
minimum stationary phase-cidal concentration 50 (MSC50) of
daptomycin is 2.5 mg/ml and the minimum stationary phase-cidal
concentration 99 (MSC99) was 9 mg/ml.
We also tested the activities of HT61, vancomycin, daptomycin
and mupirocin against non-multiplying MRSA. As shown in
Fig. 2B, HT61 at 12.5 mg/ml reduced the CFU counts of MRSA
from log 7 to 0. The MSC50 of HT61 against MRSA was 2.6 mg/
Figure 1. Growth curves of methicillin-sensitive and methicil-
lin-resistant S. aureus. The bacterium was grown in nutrient broth
medium with shaking for 10 days. The arrows indicate the timepoints
when the cultures were used for drug sensitivity test. These results were
confirmed in two independent experiments.
doi:10.1371/journal.pone.0011818.g001
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ml and the MSC99 was 6 mg/ml. However, both vancomycin and
mupirocin at 100 mg/ml showed no activity against the same
cultures. Daptomycin killed the MRSA at 50 mg/ml showing a
MSC50 at 2.5 mg/ml and a MSC99 at 9 mg/ml. The data indicate
that HT61 is more active against non-multiplying MSSA and
MRSA than commonly marketed antibiotics.
HT61 is less potent against multiplying S. aureus
The MIC of HT61 and these conventional antibiotics against
multiplying S. aureus were determined. Log phase S. aureus was very
sensitive to amoxicillin/clavulanic acid (Augmentin) (MIC 0.8 mg/
ml), azithromyicin (MIC 1.56 mg/ml), levofloxacin (MIC 0.2 mg/
ml), linezolid (MIC 0.8 mg/ml), daptomycin (1 mg/ml) and
mupirocin (MIC 0.2 mg/ml). However, HT61 is less potent
against multiplying S aureus than marketed antibiotics with an
MIC of 8 mg/ml.
Quick action of HT61 against non-multiplying S. aureus
In order to investigate the speed of kill, different concentrations
of HT61 were incubated with non-multiplying MSSA for
24 hours. At various time points, the viability of the bacteria
was examined by CFU counts. As shown in Fig. 3A, at 10 mg/ml
HT61 killed 107 S. aureus after 5 hours of treatment and at 20 mg/
ml HT61 kill the same numbers of S. aureus after one hour of
treatment. A similar speed of kill was shown for MRSA (Fig. 3B).
HT61 kills non-multiplying clinical MRSA isolates
including those which are mupirocin resistant
HT61 was tested against 103 clinical isolates of MRSA which
had been isolated from St George’s Hospital, London. HT61 was
incubated with 106 non-multiplying MRSA for 24 hours, and the
drug activity was examined by CFU counts. As shown in Table 1,
MSC50 of HT61 was 1.5 to 7.5 mg/ml against these 103 MRSA
isolates. Amongst these 103 MRSAs, there are 8 strains which
were resistant to mupirocin (5 high level and 3 low level
resistance). HT61 was active against all of the mupirocin resistant
MRSAs.
The MIC of HT61 was determined using 45 MRSA, 11
vancomycin-intermediate S. aureus (VISA) and 3 vancomycin
resistant S. aureus (VRSA) which were clinical isolates collected
Figure 2. Effects of HT61 and marketed antibiotics against
stationary phase non-multiplying MSSA and MRSA. HT61 and
the antibiotics were added to the non-multiplying cultures at different
concentrations. CFU counts were carried out after 24 hours of
incubation. A. Effects of HT61, amoxicillin/clavulanic acid, azithromyicin,
levofloxacin, linezolid, daptomycin and mupirocin against MSSA. B.
Effects of HT61, vancomycin, daptomycin and mupirocin against MRSA.
These results were confirmed in two independent experiments.
doi:10.1371/journal.pone.0011818.g002
Figure 3. Speed of kill with HT61 against non-multiplying
MSSA andMRSA. HT61 was incubated with MSSA (A) and MRSA (B) at
different concentrations for 24 hours. At different time points, CFU
counts were performed.
doi:10.1371/journal.pone.0011818.g003
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from different hospitals in the UK. As shown in Table 1, the MIC
of these MRSA, VISA and VRSA was 4 and 8 mg/ml.
HT61 was active against other gram positive bacteria
HT61 was incubated with non-multiplying stationary phase
Streptococcus pyogenes, Streptococcus agalactiae and Propionibacterium acnes
at 20, 10, 5 and 0 mg/ml for 24 hours. As shown in Fig. 4, HT61
at 20 mg/ml reduced the CFU counts of S. pyogenes and S. agalactiae
from log 6 to 0. There were more than one log kills at 10 mg/ml
for these strains. HT61 at 10 mg/ml reduced the CFU counts of S.
epidermidis and P. acnes to 0. The MICs of HT61 against these
strains were 8 mg/ml.
No resistant S. aureus was selected after long-term
treatment with HT61
The initial MSC50 for HT61 was 2.5 mg/ml when inoculated
with 107 non-multiplying MSSA. The MIC of this strain for HT61
was 8 mg/ml. Selection of resistance was performed using log
phase and stationary phase cultures which were exposed to HT61
at concentrations which were 2 fold below MIC (4 mg/ml) and
MSC50 (2.5 mg/ml), respectively. After 50 passages of exposure to
HT61, no resistance to HT61 was observed in S. aureus (data not
shown). The same MSC50 and MIC was observed at the beginning
and at the end of the selection.
HT61 has no activity against Gram negative bacteria
Bactericidal activity of HT61 was also tested against Gram
negative bacteria. The bacterial strains used were Escherichia coli,
Klebsiella aerogenes and Pseudomonas aeruginosa which were clinical
isolates from St George’s Hospital, London. HT61 was incubated
with log phase and non-multiplying bacteria at different
concentrations from 5 to 40 mg/ml. No activity of HT61 was
observed against either log-phase or stationary phase Gram
negative bacteria (data not shown).
Mechanism of action
The affect of HT61 on the cytoplasmic membrane of bacterial
cell was investigated. Log phase and 6 day old non-multiplying
stationary phase cultures were treated with the fluorescent probe
DiSC3(5) which accumulates in bacterial cells and self-quenches
its own fluorescence. HT61 at concentrations of 0.156 to 80 mg/
ml was added to DiSC3(5) treated cultures. As shown in Fig. 5A,
one minute after the addition of HT61, the fluorescence values
for the stationary phase cultures increased in a concentration
dependent manner, even at levels below the MSC50. After one
minute of treatment, the fluorescence signal did not increase
significantly. These data show that maximum depolarization of
the cytoplasmic membrane of stationary phase bacteria occurred
within 1 to 4 minutes after treatment with HT61. However, for
log-phase cultures (Fig. 5B), the release of fluorescence after
treatment of HT61 was slower than that of the stationary phase
and reached a peak after 45 minutes. It appears that the increase
of fluorescent signal was concentration dependent only at lower
concentrations of HT61. No increase in fluorescent release was
observed when HT61 reached concentrations higher than
20 mg/ml.
We then examined the ultra-structure of S. aureus by
transmission electronic microscopy after treatment with the drug.
As shown in Fig. 6B, after addition of HT61 for 10 minutes, the
cell membrane was disrupted and the cytoplasm leached out into
the extracellular space. In addition, we noticed that, after
treatment of HT61 at higher concentration, the cell wall was
nicked (Fig. 6C and Fig. 6D) and the cell contents were expelled.
HT61 kills non-multiplying MSSA and MRSA on mouse
skin
In an attempt to develop HT61 as a topical agent to clear
MSSA and MRSA, we investigated if HT61 killed MSSA and
MRSA on mouse skin. Two mouse skin models were used. The
first model was the superficial skin bacterial colonisation model.
Log phase or stationary phase MSSA or MRSA were applied onto
the intact skin of live mice at 107 CFU per 2 cm2 followed by
immediate treatment with 45 ml of HY50A (gel containing 1%
HT61) or 45 ml of Bactroban ointment (GlaxoSmithKline
containing 2% mupirocin) or 45 ml of placebo. As shown in
Fig. 7, after two hours of treatment, HT61 removed 100%
stationary phase MSSA (Fig. 7A) and 93% stationary phase
MRSA (Fig. 7B) on the mouse skin. In contrast, Bactroban showed
no activity against the same bacteria (Fig. 7A and 7B). When log
phase MSSA was applied on to mouse skin, Bactroban was more
effective than HT61 showing 100% reduction of the bacteria,
whilst HT61 killed 55% of the bacteria on the skin (Fig. 7C).
Table 1. The MSC50 and MIC of HT61 against clinically
isolated MRSA, VISA and VRSA.
MSC50
(mg/ml)
Number of
MRSA
MIC
(mg/ml)
Numbers
of MRSA
Numbers of
VISA and VRSA
1.5–1.9 26 4 32 9
2–2.9 12 8 13 5
3–3.9 30
4–4.9 19
5–5.9 5
6–6.9 5
7–7.9 4
doi:10.1371/journal.pone.0011818.t001
Figure 4. Effects of HT61 against stationary phase non-
multiplying S. pyogenes, S. agalactiae, S. epidermidis and P.
acnes. HT61 was added to the non-multiplying cultures at 20, 10, 5 and
0 mg/ml. CFU counts were carried out after 24 hours of incubation.
These results were confirmed in two independent experiments.
doi:10.1371/journal.pone.0011818.g004
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The second model which was used is the mouse superficial skin
bacterial infection model [19] in which a bacterial infection is
initiated with 107 log phase MSSA or MRSA after removal of the
upper epidermal layers. As shown in Fig. 8A, no increased growth
was seen after infection, the bacterial numbers on the infected skin
were constant during the first 24 hours, then gradually decreased.
Treatment with HT61 and Bactroban was initiated after 24 hours
of infection during which the bacteria remained stationary phase.
As shown in Fig. 7, HT61 reduced 2.91 logs of MSSA (Fig. 8B)
and 1.87 log of MRSA (Fig. 8C) after treatment for 24 hours. In
contrast, mupirocin reduced 0.86 logs of MSSA and 0.13 logs of
MRSA respectively.
Toxicity of HT61
Minipig skin was used to test HT61 for potential dermal
toxicity. These studies were conducted by LAB Research (Scantox
Denmark). After 14 days of administration of HT61 (1% gel
formulation) to 10% of the body surface of each animal, no
treatment related adverse events were seen in clinical observations
such as irritation, inflammation, itching and sensitization, body
weight and food consumption (data not shown). Furthermore, no
changes were seen before termination of treatment in clinical
chemistry, haematology, urinalysis and during ophthalmoscopy or
during electrocardiographic examination, at necropsy or at
histopathological examination. No changes were seen at histo-
pathological examination of the skin. Toxicokinetic evaluation
verified that the animals had been treated with HT61. An
accumulation of HT61 was seen between day 1 to 14 and this may
be due to saturation of the skin. Based on the Cmax and AUC0-
24h values, no dose proportionality was observed. No consistent
gender related differences were seen, although the values for the
female animals seemed higher.
Discussion
Changing the target of drug development from multiplying to
non-multiplying bacteria creates a new set of opportunities for
antibiotic development. In particular, novel classes of antibiotics
can be discovered which show bactericidal activities against non-
multiplying bacteria, but may be less potent against multiplying
bacteria. HT61 is the first example of the selection of an antibiotic
from the beginning of the development process which is active
against non-multiplying bacteria. Interestingly, HT61’s activity
against multiplying bacteria is not as potent as current marketed
antibiotics, and so it would have been rejected by conventional
anti-multiplying screening tests. In our experience, this is not an
isolated example, and we anticipate that this new method will
produce many new classes of antibiotics.
HT61 is a narrow-spectrum antibiotic which is only effective
against Gram positive bacteria. HT61 is particularly active against
S. aureus including 162 strains of MRSA which represent the major
pathogens in the world, and those that carry the Panton-Valentine
leukocidin gene. HT61 can act on multiplying bacteria, but its
MIC is higher than that of the marketed antibiotics. However, it
showed significant potency against non-multiplying organisms. For
MSSA and MRSA at 107 CFU/ml, the concentration (MSC50)
used to reduce half of the initial bacterial load was 2.5 mg/ml and
Figure 5. HT61-induced cytoplasmic membrane permeabiliza-
tion determined by the DiSC3(5) assay. Non-multiplying and log
phase MSSA were incubated with DiSC3(5) to a final concentration of
0.4 mM until no more quenching was detected, which was followed by
addition of 0.1 M KCl. Different concentrations of HT61 were incubated
with non-multiplying MSSA (A) and log phase MSSA (B). The changes in
fluorescence were monitored at various time points. The data was
confirmed in two independent experiments.
doi:10.1371/journal.pone.0011818.g005
Figure 6. Thin sectioned electron micrographs of S. aurues
analyzed by transmission electron microscopy. The cells were
fixed 10 minutes after HT61 treatment. A. normal S. aureus cells. B. HT61
at 10 mg/ml. C. HT61 at 20 mg/ml. D. HT61 at 40 mg/ml. The scale bar is
0.2 mm.
doi:10.1371/journal.pone.0011818.g006
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the concentration to achieve a 99% kill (MSC99) is 4.5–6 mg/ml.
The concentration required to achieve a complete kill was
12.5 mg/ml. The potency of HT61 was significantly higher than
that which has been reported for the anti-stationary phase agent
daptomycin [20] that required 50 mg/ml to completely kill
stationary phase MSSA and MRSA (Fig. 2). Due to its combined
action against multiplying and non-multiplying bacteria, HT61
has the potential to treat an infection with a mix of organisms that
are in different growth phases. Although HT61 has lower
bactericidal activity against multiplying bacteria than marketed
antibiotics, it is used in such a high concentration in its topical
formulation (currently 1% v/v, 10 mg/ml) that this should
compensate for this weakness.
Figure 7. Effect of HT61 against MSSA and MRSA in a murine
skin bacterial colonization model. Stationary phase MSSA (A) and
MRSA (B) were applied onto 2 cm2 skin area followed by addition of
HT61 gel, Bactroban and placebo (control) for 2 hours. Log phase MSSA
were treated with HT61 gel, Bactroban and placebo (control) for
2 hours on mouse skin (C). The data has been repeated twice.
doi:10.1371/journal.pone.0011818.g007
Figure 8. Effect of HT61 against MSSA and MRSA in a murine
skin bacterial infection model. A. After tape-stripping the skin, log
phase MSSA was applied onto the skin area. At different time points
CFU counts of the bacteria were determined. The arrow indicates the
point which the treatment was initiated. B. Treatment of HT61,
Bactroban and placebo (control) against MSSA and C. Treatment of
HT61, Bactroban and placebo (control) against MRSA. **, P,0.01. The
data has been repeated twice.
doi:10.1371/journal.pone.0011818.g008
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The precise mode of action of HT61 has not been demonstrated
as yet. However, cell membrane depolarization of S. aureus was
observed after treatment with HT61. The compound acts on the
bacterial cell cytoplasmic membrane by disruption of S. aureus’s cell
membrane potential, and this leads to the release of the cellular
contents. Furthermore, HT61 also acts on the bacterial cell wall.
After 10 minutes of treatment, the cell wall structure is nicked
when HT61 is used at higher concentrations. This suggests that
HT61 has several mechanisms of action, whose targets lie in the
bacterial cell cytoplasmic membrane and the cell wall. Further
investigation into the mode of HT61 action is under way in our
laboratory.
The most important property of HT61 is its activity in animal
models of S aureus skin infection. In animals infected with
multiplying and non-multiplying bacteria which had been applied
to normal skin, 106 or more bacteria were killed by a single
application of the antibiotic at a 1% concentration. In contrast,
mupirocin at 2% concentration failed to kill the non-multiplying
organisms. In animals which had skin partially stripped prior to
application of bacteria, the bacterial load remains relatively
constant after infection during the first 48 hours, indicating that
the bacteria stay non-multiplying or slowly multiplying. A 102–103
CFU bactericidal effect was also seen with HT61 but Mupirocin
barely had any effect.
Examination of the clinical usefulness of HT61 in man is now
under way. This antibiotic will be used topically at high
concentration (10 mg/ml). At these concentrations, it is anticipat-
ed that it will be bactericidal for both multiplying and non-
multiplying bacteria. This means that it may be useful as a stand-
alone antibiotic. On the other hand, better results may be obtained
by using it in combination with another antibiotic which is active
against multiplying bacteria. The combination should remove the
entire population of targeted bacteria. The best examples of
combinations of anti-multiplying and anti-non-multiplying antibi-
otics are in tuberculosis chemotherapy [21,22,23,24], where
isoniazid (kills multiplying bacteria) and pyrazinamide (kills non-
multiplying or persistent organisms), are used side by side, together
with other antibiotics such as rifampicin and ethambutol.
HT61 will be used clinically to decolonize the nose for S aureus,
including MRSA. Potential advantages over the market leader,
mupirocin, are as follows: Firstly, HT61 is active against
mupirocin resistant bacteria. In countries such as Spain,
mupirocin resistance is so high, that it is no longer used in many
hospitals [25]. It is likely that widespread use of mupirocin in the
rest of the world will result in an increase in mupirocin resistance
in many countries. Mupirocin resistance can occur at high level or
low level [26,27,28,29,30]. This type of resistance is associated
with bacteriological relapse in the nose within a shorter period of
time than for sensitive strains [31]. Whilst low level mupirocin
resistance can be induced in vitro in the presence of increasing
concentrations of mupirocin [32,33], we have demonstrated that
no HT61 resistant strains were obtained after 50 passages of
selection during the period of log phase and stationary phase
growth. Secondly, HT61 may be able to shorten the duration of
therapy in situations where non-multiplying bacteria are present.
In comparison to marketed antibiotics, HT61 is about one million
times more potent against non-multiplying S. aureus. In vitro and in
animal models, HT61 shortens the duration of therapy, but it is
not known whether this will occur in humans. However, it is likely
that populations of bacteria, other than multiplying ones in log
phase exist on the human skin. For example, if all the bacteria on
the human skin were multiplying, it would be expected that
overnight growth would be so rapid that colonies would be visible
in the morning. Clearly this is not the case, which suggests that,
perhaps due to lack of nutrients and other essential growth factors,
bacteria do not usually multiply rapidly on human skin, or in the
nose. Indeed, we show (Fig 8A) here that bacteria on mouse skin
after infection did not sustain growth. In other diseases, such as
tuberculosis [34], bacterial endocarditis [35,36,37] and biofilms on
intravenous catheters [38,39] mixed populations of bacteria are
known to co-exist. Whether this also applies to the skin and to the
nose is not known. Thirdly, it may be possible to reduce the rate of
emergence of resistance. Shortening of the course of antibiotic
therapy itself may reduce the emergence of resistance because it is
known that long courses can be associated with the emergence of
resistance, for example due to poor patient compliance. HT61 acts
fast, and this may reduce the chance of emergence of resistance.
This antibiotic also acts against the cell membrane and the cell
wall, and resistance emergence to this compound may be lower
than other antibiotics which target a single enzyme, such as
rifampicin or mupirocin [40,41,42,43,44]. Combination of HT61,
or similar compounds with antibiotics which kill multiplying
bacteria, may prolong the useful life of such partner antibiotics
because, if the combination of the two antibiotics kill the entire
bacterial target population faster than each on its own, the rate of
resistance emergence may be slowed [45,46]. After all, dead
bacteria cannot mutate. Another way of prolonging the useful life
of existing antibiotics, such as mupirocin, would be to use the
existing antibiotic once only in an individual, and then use HT61
for treatment of relapses. In this way, repeated exposure of
bacteria in one individual, a sure way to induce resistance, would
be limited. Fourthly, HT61 may lengthen the period before
relapse occurs. In the nose, S. aureus including MRSA can be
removed by the use of mupirocin [31]. However, if the bacteria
are resistant to mupirocin, relapse occurs within a few weeks [47].
For sensitive organisms, there is a 30% relapse rate at three
months, and by six months, 50% have relapsed [48]. The fact that
patients who are colonized with mupirocin resistant bacteria
relapse early with mupirocin resistant strains suggests that these
persist in the nose. It is not known what proportion of patients who
relapse with sensitive bacteria, do so as a result of relapse of
persistent bacteria in the nose, or auto-infection from another site
in the body, such as the finger. Since the initial strains are usually
the same as the relapse strains [49], it is thought re-infection from
other people or other sources is less likely than autoinfection.
In conclusion, this paper describes the properties of a novel
antibiotic which has been produced by a new approach, namely,
by selecting, from the beginning of the discovery process,
compounds which are active against non-multiplying bacteria.
This method should be able to yield many new classes of
antibiotic. In addition, these antibiotics may be able to reduce the
rate of emergence of resistance, shorten the duration of therapy,
and reduce relapse rates.
Materials and Methods
Bacterial strains and growth conditions
Bacterial strains used in this study are list as following; Oxford,
S. aureus NCTC 6571 (methicillin-sensitive), methicillin-resistant S.
aureus (MRSA NCTC 12493), MRSA strains (clinical isolates from
St George’s Hospital, London), S. epidermidis (NCTC 5955), S.
pyogenes (NCTC 10867), S. agalactiae (NCTC 8542), P. acnes (NCTC
737) and Gram-negative bacteria, such as E. coli, K. aerogenes and P.
aeruginosa (clinical isolates from St George’s Hospital, London).
The strains of Staphylococci and Gram-negative bacteria were grown
in nutrient broth (Oxoid) or on blood agar plates and the strains of
Streptococci and P. acnes were grown in brain heart broth (Oxoid) or
on blood agar plates.
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Antibiotics and drug-like compounds
Antibiotics were used as follow: Augmentin (1.2 g containing
co-amoxiclav 1000/200, GlaxoSmithKline), Azithromycin (Zi-
thromaxTM suspension, 40 mg/ml, Pfizer), Levofloxacin (Tava-
nicH 5 mg/ml Hoechst Marion Roussel), Linezolid (2 mg/ml
Zyvox, Pharmacia), daptomycin (Cubicin, Novartis) and Mupir-
ocin (Sigma). 56 quinolone-like compounds were obtained from
Bionet Research, Butt Park Ltd, Maybridge, Enamine and Specs.
HT61 was synthesed by Argenta Discovery UK. Stock solutions of
the tested compounds were prepared in dimethyl sulfoxide to
10 mg/ml.
Susceptibility test of antibiotics against exponentially
growing bacteria
The minimum inhibitory concentration (MIC) was determined
by the broth dilution method in Iso-Sensitest broth (Oxoid)
following the Clinical and Laboratory Standards Institute
guidelines for broth microdilution MIC. A physiological level of
50 mg/L Ca2+ was supplemented to Iso-Sensitest broth when
testing daptomycin. MIC value was defined as the lowest
concentration resulting in 90% inhibition of growth.
Susceptibility test of antibiotics against stationary phase
non-multiplying bacteria
The methicillin-sensitive S. aureus (MSSA), methicillin-resistant
S. aureus (MRSA), S. epidermidis and Gram negative strains were
cultured in nutrient broth over-night at 37uC. Two hundred
microliters of the overnight cultures were used to inoculate 100 ml
of nutrient broth. Then the cultures were continuously shaken at
110 rpm at 37uC for 10 days. For growth of S. pyogenes and S.
agalactiae, a serial of 10 ml brain heart broth was inoculated with
the overnight cultures, and then the cultures were incubated
without shaking for 6 days. For growth of P. acnes, the broth
cultures and the blood agar plates were incubated under anaerobic
conditions for 5 days. Viability was determined by plating 100 ml
of serial dilutions onto nutrient agar (Oxoid) plates or blood agar
plates and was expressed as colony forming units (CFU) per
milliliter. The CFU was counted using aCOLyte colony counter
(Synbiosis) and analyzed using the software came with the counter.
To test antibiotic activities against stationary phase non-multiply-
ing bacteria, the 5–6 day old cultures were washed with phosphate
buffered saline (PBS) and diluted in the same buffer to 106 or 107
CFU/ml which was served as cell suspension for drug sensitivity
test. For testing of daptomycin, a physiological level of 50 mg/L
Ca2+ was supplemented. The cell suspension was added in each
well of a 96-well microtiter plate incubated with different
concentrations of the drugs in triplicate to a final volume of
300 ml. At different time points after drug incubation, the cultures
were washed three times with PBS and were resuspended in the
original volume. The activities of the drugs against stationary
phase non-multiplying bacteria were determined as minimum
stationary phase-cidal concentration 50 (MSC50) [5] which is
defined as the concentration of the drug leading to a reduction in
half of the initial bacterial counts and minimum stationary phase-
cidal concentration 99 (MSC99) which is defined as the
concentration resulted in reduction of 99% initial bacterial counts.
Multistep selection of resistance
The bacteria were cultured in nutrient broth over-night at
37uC. 20 microlitres of the overnight culture were used to
inoculate 10 ml of nutrient broth which was incubated for 5–6
days. The drug was added into the stationary phase culture to a
concentration which was 2-fold below its MSC50. After two days of
exposure, 200 ml of the culture was added to 10 ml of fresh
nutrient broth, at the same time the drug was added to the final
concentration which was 2-fold below its MIC. After drug
exposure for 4 days, single colonies were picked and sensitivity
test was carried out against both stationary phase non-multiplying
and log phase cultures. During this procedure, the drug was
exposed to both log phase and stationary phase cultures. Fifty
passages of drug exposure, as described above, were performed to
select drug resistant bacterial strains.
Fluorescent assay to measure cytoplasmic membrane
potential
Cell membrane permeability was measured using a fluorescent
assay as described previously [50]. Log phase or stationary phase
cultures were harvested and washed with PBS. The bacterial cells
were resuspended with PBS to an optical density of 0.05 at
600 nm. The cell suspension was incubated with 0.4 mMDiSC3(5)
(Dipropylthiacarbocyanine) (Sigma), a membrane potential sensi-
tive cyanine dye, until a stable (approximately 90%) reduction in
fluorescence was reached as a result of DiSC3(5) uptake and
quenching in the cell due to an intact membrane potential. Then
100 mM KCl was added into the cell suspension to equilibrate the
intracellular and external K+ concentrations. The samples were
placed into wells of a 96 well flat bottom fluorescence microtitre
plate (Fischer Scientific UK) followed by addition of different
concentrations of drug in triplicates. Fluorescence was monitored
using a fluorescence spectrophotometer (Applied Biosystem) at an
excitation wavelength of 622 nm and an emission wavelength of
670 nm. The induction of fluorescence, which resulted from the
disruption of the cytoplasmic membrane by different concentra-
tions of drugs, was recorded. The background was subtracted
using a control which contained only the cells and the dye.
Electron Microscopy
Bacterial cultures were harvested and fixed with a fixation
solution containing 2% formaldehyde and 2% glutaraldehyde,
0.2 M sucrose in 0.1 M cacodylate (pH 6.9) buffer. Sample
processing, sectioning and examination of the transmission
electron microscope were performed in the Ultrastructural
Imaging Unit, King’s College London.
Superficial skin bacterial colonization and infection
models
The skin bacterial colonization and infection models were
performed using female ICR mice (6 to 8 weeks old) obtained from
Harlan, UK Ltd. The animal husbandry and animal care
guidelines were followed according to the Animals Scientific
Procedures Act, 1986 (an Act of the Parliament of the United
Kingdom 1986 c. 14). The study was specifically approved by the
animal ethical committee of St George’s University of London.
For the intact skin bacterial colonization model, ICR mice were
anesthetized by intraperitoneal injection of 200 ml of a 1:1:2
mixture of 100 mg/ml ketamine hydrochloride, 20 mg/ml
xylazine, and sterile water. The fur of the mice on the back was
removed by an electric clipper. A two cm2 skin area was marked
with a marker pen and log-phase or stationary phase cultures (20
to 30 ml) were added on the 2 cm2 area. The bacterial suspension
on the skin was allowed to dry for 20 minutes. Treatment of the
bacteria was performed by spreading 45 ml of gels or ointment on
the skin. The superficial damaged skin infection model was
performed as described previously [19] with the following
modifications. After anesthetizing the mouse and removing its
fur on the back, an area of 2 cm2 skin is tape stripped using an
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autoclave tape. The skin was striped 10 times in succession. This
procedure damaged the skin by removing the top dermal layers,
which became red and shiny, but without observable bleeding.
Buprenorphine was given at 0.2 mg/kg body weight during the
anesthetic period and every 12 hours for up to 3 days to reduce
pain. Bacterial infection was induced by the addition of 10 to 25 ml
of log phase culture containing 107 bacterial cells on the stripped
skin. At 24 hours after infection, treatment with gels or ointment
was initiated. At different time points after infection and
treatment, 3 or 4 mice were sacrificed by cervical dislocation.
The skin, approximately 2 cm2 was cut and added to 2 ml tubes
which contained 1 ml water and glass beads (1 mm). The skin was
homogenised using a reciprocal shaker (Fisher Scientific UK) for
45 second (6.5 speed). Antibiotic remaining on the skin was
removed by washing 3 times with water. CFU counts were
performed on serial dilutions of the homogenates.
Dermal toxicity study
The dermal toxicity of the compounds was performed by LAB
Research (Scantox Denmark). Twenty-four Go¨ttingen SPF mini-
pigs (12 males and 12 females) were used for the study which were
obtained from Ellegaard Go¨ttingen Minipigs ApS, Denmark. The
animals were approximately 3 months old and the body weight
was 6.0 to 8.4 kg. They were allocated to 4 groups each consisting
of 3 males and 3 females. HT61 was administered daily by dermal
application to for 14 days. The dose for the treatment was 1 g/kg/
day on 10% of the body surface area. Clinical signs, dermal
reactions and food consumption were recorded daily. The body
weight was recorded weekly, and in addition, on the day of
necropsy.
Before and after treatment, blood and urine samples were taken
from all animals for clinical chemistry, haematology and urinalysis.
Also the animals were subjected to an electrocardiographic and
ophthalmoscopic examination. Blood taken from day 1 and day 14
was also used for toxicokinetic analysis. At the end of the
experiment, the animals were anaesthetised, euthanized by
exsanguination and subjected to macroscopic necropsy. Selected
organs or tissues were weighed, sampled, fixed and examined
microscopically.
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